-
Gossamer Bio NASDAQ:GOSS Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
Location: 3013 Science Park Rd, California, 92121-1101, US | Website: www.gossamerbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
51.23M
Cash
354.5M
Avg Qtr Burn
-968K
Short % of Float
3.71%
Insider Ownership
2.95%
Institutional Own.
81.17%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Lung disease, Pulmonary hypertension associated with interstitial lung disease | Phase 3 Initiation | |
Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor) Details Pulmonary arterial hypertension, Lung disease, Rare diseases | Phase 2 Data readout | |
GB004 (Oral HIF-1α stabilizer) Details Ulcerative colitis | Failed Discontinued | |
GB1275 (Oral CD11b modulator) Details Solid tumor/s, Esophageal cancer, Cancer, Gastric cancer | Failed Discontinued | |
Failed Discontinued |